Oncology

Louisiana local Ronnie Schwartz clinches St. Jude Hero Among Us Award

Retrieved on: 
Saturday, December 3, 2022

The 2022 St. Jude Hero Among Us Award was presented to Ronnie Schwartz of Alexandria, LA., a selfless champion for St. Jude kids, on the eve of St. Jude Memphis Marathon Weekend presented by Juice Plus+ .

Key Points: 
  • The 2022 St. Jude Hero Among Us Award was presented to Ronnie Schwartz of Alexandria, LA., a selfless champion for St. Jude kids, on the eve of St. Jude Memphis Marathon Weekend presented by Juice Plus+ .
  • The award is given each year to a St. Jude Hero who rallies others to raise funds for St. Jude Childrens Research Hospital .
  • View the full release here: https://www.businesswire.com/news/home/20221202005504/en/
    The 2022 St. Jude Hero Among Us Award was presented to Ronnie Schwartz of Alexandria, LA., a selfless champion for the kids and families of St. Jude Children's Research Hospital, on the eve of St. Jude Memphis Marathon Weekend.
  • In 2020, Schwartz was recognized with the St. Jude Hero of the Year Award for his overall support of the St. Jude mission.

Global Lung Cancer Screening Software Market Report 2022: Growing Awareness about Screening Programs Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Friday, December 2, 2022

The Global Lung Cancer Screening Software Market is segmented based on Cancer Type, Diagnosis Type, End-Users, and Geography.

Key Points: 
  • The Global Lung Cancer Screening Software Market is segmented based on Cancer Type, Diagnosis Type, End-Users, and Geography.
  • By Cancer Type, the market is classified into Non-Small Cell Lung Cancer, and Small Cell Lung Cancer.
  • The report presents a detailed Ansoff matrix analysis for the Global Lung Cancer Screening Software Market.
  • The report offers a comprehensive evaluation of the Global Lung Cancer Screening Software Market.

Global Flow Cytometry Market Report 2022: Rise In The Adoption Of The Flow Cytometry Approach In Academia And Research Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, December 2, 2022

The Global Flow Cytometry Market size is expected to reach $7.7 billion by 2028, rising at a market growth of 8.3% CAGR during the forecast period.

Key Points: 
  • The Global Flow Cytometry Market size is expected to reach $7.7 billion by 2028, rising at a market growth of 8.3% CAGR during the forecast period.
  • The market for flow cytometry has experienced rapid expansion as a result of the rising prevalence of chronic and infectious disorders.
  • The sample must be a single-cell suspension, which is the most important condition for effective and efficient flow cytometry analysis.
  • One of the elements anticipated to propel the flow cytometry market in the coming years is the rising prevalence of certain disorders.

BostonGene Announces Presentations at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition

Retrieved on: 
Friday, December 2, 2022

Time and Location: Monday, December 12 | 6:00 PM-8:00 PM, Hall D

Key Points: 
  • Time and Location: Monday, December 12 | 6:00 PM-8:00 PM, Hall D
    Research conducted by Memorial Sloan Kettering Cancer Center and BostonGene.
  • In addition to the poster presentations, the abstracts have been published online in the November supplemental issue of Blood .
  • BostonGene Tumor Portrait Tests reveal key drivers of each tumor, including immune microenvironment properties, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies.
  • Through these comprehensive analyses, BostonGene Tumor Portrait Tests generate a personalized roadmap for therapeutic decision-making for each cancer patient.

Everest Clinical Research Announces the Acquisition of Brightech International

Retrieved on: 
Friday, December 2, 2022

Everest Clinical Research (Everest), a leading full-service contract research organization (CRO) with deep expertise in biostatistics and statistical programming, today announced it has acquired Brightech International (Brightech).

Key Points: 
  • Everest Clinical Research (Everest), a leading full-service contract research organization (CRO) with deep expertise in biostatistics and statistical programming, today announced it has acquired Brightech International (Brightech).
  • Founded in 2002, Brightech is a leading CRO that specializes in complex, value-add biostatistics, programming and clinical data management services.
  • Similar to Everest, Brightech has earned a highly-regarded reputation as a critical partner for some of the worlds largest pharmaceutical and biotech companies.
  • Everest is a full-service contract research organization (CRO) providing a broad range of expertise-based clinical research services to worldwide pharmaceutical, biotechnology, and medical device industries.

UroGen Announces New Data from the OPTIMA II Study that Show Median Durability of Response of 24.4 Months for UGN-102, an Investigational Non-Surgical Chemoablative Treatment for Low-Grade, Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Retrieved on: 
Friday, December 2, 2022

I look forward to additional data on UGN-102, including evidence from the ENVISION Phase 3 study.

Key Points: 
  • I look forward to additional data on UGN-102, including evidence from the ENVISION Phase 3 study.
  • Patients who completed the OPTIMA II study were eligible to participate in this rollover study.
  • At the time of data cut off (February 25, 2022), data were available for 15 of the 25 patients.
  • Patients achieving CR were followed quarterly to 12 months after initiation of study treatment to evaluate safety, efficacy, and durability.

Bring Your Passion to Our Mission: More Than 20,000 Participants, Record Number of St. Jude Families to Run St. Jude Memphis Marathon Weekend

Retrieved on: 
Friday, December 2, 2022

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20221202005080/en/
    St. Jude Memphis Marathon Weekend is the largest single day fundraiser for St. Jude Childrens Research Hospital.
  • Since its inception in 2002, St. Jude Memphis Marathon Weekend has grown into a celebration of community ties and relationships to St. Jude and Memphis that endure year after year.
  • Get full St. Jude Memphis Marathon Weekend details and donate to St. Jude at stjude.org/marathon .
  • Support the St. Jude mission by donating at stjude.org , liking St. Jude on Facebook , following St. Jude on Twitter , Instagram , LinkedIn and TikTok , and subscribing to its YouTube channel.

Adicet Bio to Host Investor Webcast to Discuss Updated Clinical Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)

Retrieved on: 
Friday, December 2, 2022

The live webcast of the presentation can be accessed by registering under Presentations & Events in the investors section of the Companys website at https://www.adicetbio.com .

Key Points: 
  • The live webcast of the presentation can be accessed by registering under Presentations & Events in the investors section of the Companys website at https://www.adicetbio.com .
  • Upon registration, all participants will receive a confirmation email with a unique passcode to provide access to the webcast event.
  • To participate via telephone, please join by dialing 1-833-548-0276 (domestic) or 1-646-876-9923 (international) and referencing the conference ID 98173615816.
  • Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer.

Bio-Thera Solutions Announces BAT8006 (Folate-Receptor-α-ADC) and BAT8008 (Trop2-ADC) Poster Presentations at the 2022 San Antonio Breast Cancer Symposium

Retrieved on: 
Friday, December 2, 2022

Bio-Thera Solutions, a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and a pipeline of biosimilars, today announced the company will present two posters at the 2022 San Antonio Breast Cancer Symposium (SABCS) taking place December 6 - 10, 2022 in San Antonio, Texas.

Key Points: 
  • Bio-Thera Solutions, a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and a pipeline of biosimilars, today announced the company will present two posters at the 2022 San Antonio Breast Cancer Symposium (SABCS) taking place December 6 - 10, 2022 in San Antonio, Texas.
  • Folate Receptor is a naturally occurring receptor that is overexpressed in many types of cancer, including breast cancer and ovarian cancer.
  • Trop-2 is a naturally occurring receptor that is overexpressed in many types of cancer, including triple negative breast cancer and gastric cancer.
  • This news release contains certain forward-looking statements relating to BAT8006, BAT8008 or the product pipelines in general of Bio-Thera Solutions.

Bio-Thera Solutions Announces Presentation of BAT8009 (B7-H3-ADC) at the 2nd Annual ADC Target Selection Summit

Retrieved on: 
Friday, December 2, 2022

Other new ADC assets developed using this next-gen ADC platform include BAT8006 (Folate-Receptor-alpha-ADC), BAT8007 (Nectin4-ADC), BAT8008 (Trop2-ADC) and BAT8010 (Her2-ADC).

Key Points: 
  • Other new ADC assets developed using this next-gen ADC platform include BAT8006 (Folate-Receptor-alpha-ADC), BAT8007 (Nectin4-ADC), BAT8008 (Trop2-ADC) and BAT8010 (Her2-ADC).
  • All of these ADC assets are currently in, or about to begin, Phase 1 clinical trials.
  • BAT8009 is being developed for use as a single agent and in combination with other agents for the treatment of multiple cancers.
  • This news release contains certain forward-looking statements relating to BAT8009 or the product pipelines in general of Bio-Thera Solutions.